Gail S. Page
President & Chief Executive Officer
Ms. Page is a diagnostics industry veteran with over 30 years executive experience. She has served in executive leadership roles including commercialization, business development and general management. She is responsible for leading the company and the development and commercialization of OVA1®, as well as the discovery, development and commercialization of other novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients.
|
|
Read more
|
 |
|
Eric Fung, MD, PhD
Chief Medical Officer
Dr. Fung joined Vermillion in May 2000 as a lead scientist in the Biomarker Discovery Centers and was promoted to Vice President and Chief Science Officer in June 2006 where he was responsible for leading the successful OVA1® prospective clinical trial. Dr. Fung was appointed as Senior Vice President and Chief Medical Officer in October 2011.
|
|
Read more
|
|
Donald G. Munroe, Ph.D.
Vice President, Research & Development & Chief Scientific Officer
Dr. Munroe has extensive experience in the diagnostic industry and has been a key member of senior management in a number of prominent diagnostic and life science companies. He served as Vice President, Immunoassay Research and Development from 2009 to 2011 at Beckman Coulter, a preeminent manufacturer of automated diagnostic tests and biomedical instruments. In this role, Dr. Munroe was responsible for launching key Immunoassay menu additions and re-standardizing existing assays.
|
|
Read more
|
|
William B. Creech
Vice President, Sales & Marketing
Mr. Creech was hired in March 2010 as the VP of Sales and Marketing. Most recently, Mr. Creech was VP Sales & Marketing at Capitol Vial, a subsidiary of Thermo Fisher Scientific, from March 2005 until September 2008. From March 1998 until March 2005, Bill was VP Corporate Accounts for Apogent Technologies and continued in that role when they were acquired by Fisher Scientific. He served as Director of Corporate Accounts at Chiron Diagnostics from 1995 to 1998.
|
|
Read more
|
|
Ashish Kohli
Vice President, Corporate Strategy
Mr. Kohli joins Vermillion most recently from Columbia Wanger Asset Management where he served as a Buy- Side Equity Analyst from July 2005 to June 2010. From 2000 through 2005 he worked at William Blair & Company, the first three years as a Sell-Side Equity Associate and the last two years as a Sell-Side Equity Analyst. Previously, he held an Emerging Markets Debt analyst position at Brinson Partners, Inc. Mr. Kohli received his Master of Business Administration from Texas Tech University and his Bachelor of Science in Computer Engineering and Bachelor of Science in Biochemistry from McMaster University in Hamilton, Ontario. |
Eric Schoen
Chief Accounting Officer
Mr. Schoen joined Vermillion in July 2010 as Corporate Controller. Prior to joining the Company, Mr. Schoen served as Revenue Controller for Borland Software from 2007 to 2010. From 2000 to 2007, he served in Corporate Controller and Director of Finance roles for Trilogy Enterprises, Momentum Software and Alticast, Inc. Mr. Schoen also spent nine years with PricewaterhouseCoopers, most recently as a Manager in the audit and assurance, transaction services and global capital markets practices. Mr. Schoen received his Bachelor of Science in Finance from Santa Clara University. |
|
|
|
|
|
